FDA Shuts Down Emergency Use for Major COVID Antibody Drugs
Published Date: 7/29/2025
Notice
Summary
The FDA has officially ended the emergency use of several COVID-19 antibody treatments from Regeneron, GSK, Lilly, and AstraZeneca as of December 13, 2024. This means these drugs can no longer be used under emergency rules, affecting patients and healthcare providers relying on them. The change reflects updated safety and effectiveness info, so folks should look for other treatment options moving forward.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
EUA Revoked for Four COVID Antibodies
On December 13, 2024, the FDA revoked the Emergency Use Authorizations for REGEN-COV (casirivimab and imdevimab), sotrovimab, bebtelovimab, and EVUSHELD (tixagevimab co-packaged with cilgavimab). This means these drugs can no longer be used under emergency rules and may affect patients and health care providers who relied on them.
Revocations Cited Safety/Effectiveness; Find Alternatives
The FDA said the revocations reflect updated safety and effectiveness information and advises people who used or would have used these treatments to look for other treatment options going forward. The revocations took effect December 13, 2024.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16944, Gardenia Blue Interest Group; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by Gardenia Blue Interest Group (GBIG or petitioner), c/o Exponent, Inc., proposing that we amend our color additive regulations to expand the safe use of gardenia (genipin) blue in various foods at levels consistent with good manufacturing practice. The petition also proposes to lower the specification for arsenic in gardenia (genipin) blue.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16943, International Association of Color Manufacturers; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by the International Association of Color Manufacturers, proposing that we amend our color additive regulations to provide for the safe use of acetone as a solvent in the manufacture of carrot oil. The petition also proposes to add heavy metal limits and secondary names for carrot oil. FDA may also consider other changes to the regulation, as appropriate, during the course of our review.
Previous / Next Documents
Previous: 2025-14232, Freight Rail Couplers and Parts Thereof From Czech Republic and India; Institution of Antidumping and Countervailing Duty Investigations and Scheduling of Preliminary Phase Investigations
The U.S. is launching investigations to see if freight rail couplers from the Czech Republic and India are being unfairly sold or subsidized, which might hurt American businesses. If problems are found, extra taxes could be added to these imports. The first big decision is due by September 8, 2025, so things are moving fast!
Next: 2025-14234, Self-Regulatory Organizations; The Nasdaq Stock Market LLC; Notice of Filing of Proposed Rule Change To Amend the Hashdex Nasdaq Crypto Index US ETF To Allow for In-Kind Transfers Under Nasdaq Rule 5711(d) (Commodity-Based Trust Shares)
Nasdaq wants to update the Hashdex Nasdaq Crypto Index US ETF so it can swap bitcoin and ether 'in-kind' instead of just cash. This change helps investors trade more smoothly and could save money on fees. The new rule is up for review now and, if approved, will make crypto ETF trading easier and more efficient starting soon.